Current Affair 1:

News:

India formally launched the first indigenous antibiotic "Nafithromycin" for resistant infections.

The antibiotic "Nafithromycin" has been developed with the support of "Biotechnology Industry Research Assistance Council" (BIRAC), a unit of the Department of Biotechnology and has been brought to market under the trade name "Miqnaf".

It is the country's first indigenously developed antibiotic to tackle Antimicrobial Resistance (AMR).

This innovation is designed to treat Community-Acquired Bacterial Pneumonia (CABP), a severe illness caused by drug-resistant bacteria, which disproportionately affects vulnerable populations, including children and the elderly as well as immune-compromised hosts like Patients with Diabetes, Cancers, etc.

Nafithromycin’s efficacy stands out as it targets typical and atypical pathogens, offering a potent solution where no new antibiotic in this class has been developed worldwide for over three decades.

The development of Nafithromycin represents 14 years of dedicated research and an investment of ₹500 crores, with clinical trials spanning the U.S., Europe, and India.

<< Previous Next >>